TASLY(SH:600535) 智通财经网·2025-09-22 08:29Core Viewpoint - Tianjin Tasly Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its innovative drug, recombinant human urokinase (Puyouke), to be used for thrombolytic treatment of acute ischemic stroke, expanding its market potential and product line in the neurology/psychiatry sector [1] Group 1 - The company’s subsidiary, Tasly Biopharmaceuticals, has been granted a drug registration certificate for Puyouke, which now has a new indication for acute ischemic stroke [1] - Puyouke is the only approved recombinant human urokinase product in China and is the first class of innovative biological drug supported by the national "Major New Drug Creation" project during the "11th Five-Year Plan" [1] - The approval of the new indication enhances the company's product offerings and competitiveness in the market by targeting a broader patient population [1]